Scholarlink

<p>Relapsed/refractory classical Hodgkin lymphoma (r/r cHL) poses a therapeutic challenge, particularly after failure of checkpoint inhibitors (CPIs) and brentuximab vedotin. We report a case of a heavily pretreated young male patient with r/r cHL who achieved complete metabolic response (CMR) after allogeneic hematopoietic stem cell transplantation (allo-HCT) following pembrolizumab and bendamustine therapy, currently in CMR at 19 months post-transplantation. Despite prior resistance to nivolumab, pembrolizumab combined with bendamustine contributed to disease control in the pre-transplant period. This case highlights allo-HCT’s curative potential even in partial responders and suggests that pre-transplant CPI therapy may enhance the graft-versus-lymphoma effect, improving post-transplantation outcomes in r/r cHL. Another explanation for the therapeutic success may be that the employment of a CPI has likely contributed to sensitization to chemotherapy and bendamustine potentially lowering the occurrence of GvHD due to T-cell compartment impairment, with the need for large scale prospective trials to demonstrate our findings.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Allogeneic stem cell transplantation with prior pembrolizumab and bendamustine therapy induce complete metabolic response in relapsed/refractory classical hodgkin lymphoma with relapse after nivolumab

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月30日

查看全文
  • Ugo Giordano,
  • Agnieszka Kuś,
  • Karolina Kędziora,
  • Mateusz Sawicki,
  • Zbigniew Podgajny,
  • Monika Mordak-Domagała,
  • Zuzanna Dybko,
  • Jarosław Dybko

摘要

Relapsed/refractory classical Hodgkin lymphoma (r/r cHL) poses a therapeutic challenge, particularly after failure of checkpoint inhibitors (CPIs) and brentuximab vedotin. We report a case of a heavily pretreated young male patient with r/r cHL who achieved complete metabolic response (CMR) after allogeneic hematopoietic stem cell transplantation (allo-HCT) following pembrolizumab and bendamustine therapy, currently in CMR at 19 months post-transplantation. Despite prior resistance to nivolumab, pembrolizumab combined with bendamustine contributed to disease control in the pre-transplant period. This case highlights allo-HCT’s curative potential even in partial responders and suggests that pre-transplant CPI therapy may enhance the graft-versus-lymphoma effect, improving post-transplantation outcomes in r/r cHL. Another explanation for the therapeutic success may be that the employment of a CPI has likely contributed to sensitization to chemotherapy and bendamustine potentially lowering the occurrence of GvHD due to T-cell compartment impairment, with the need for large scale prospective trials to demonstrate our findings.